Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Univ. of Bonn HDAC6 compound 17c
- Development stage
- Unknown
- Lead developer
- University of Bonn
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules
01
Overview
Univ. of Bonn HDAC6 compound 17c: sourced facts only. name: "Among these, 17c was the most effective, achieving an HDAC6 degradation of 91% and a DC50 value of 14 nM." [PMID:40104802]; target: "Among these, 17c was the most effective, achieving an HDAC6 degradation of 91% and a DC50 value of 14 nM." [PMID:40104802]; developer: "Department of Pharmaceutical and Cell Biological Chemistry, Pharmaceutical Institute, University of Bonn, 53121 Bonn, Germany." [PMID:40104802]; modality: "In this study, we present the development of HDAC6-directed proteolysis-targeting chimeras (PROTACs) featuring an ethyl hydrazide moiety as an alternative ZBG." [PMID:40104802]
02
Targets
HDAC6 (Histone deacetylase 6)
Beyond the preview
Go deeper on Univ. of Bonn HDAC6 compound 17c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Univ. of Bonn HDAC6 compound 17c.